OMER · Omeros Corp · Insider Trading

No portion of the option was vested, and no shares were issued, on the grant date. The shares subject to the option will vest and become exercisable in four equal tranches subject to both (i) achievement of stock-price hurdles of $25.00, $30.00, $35.00 and $40.00 per share, respectively, calculated based on the aggregate volume-weighted average price of the registrant's common stock over 30 consecutive trading days, taken as a single measurement period, at any point during the option's five-year term, and (ii) satisfaction of a continued-service condition under which 25% of the shares in each tranche will become eligible for vesting on the first anniversary of the grant date and the remainder will become eligible for vesting in equal monthly installments over the following 36 months. The stock-price hurdles represent appreciation of approximately 40%, 68%, 96% and 124%, respectively, above the grant-date closing price of $17.88 per share, which is also the option's exercise price.

This option vested and became exercisable with respect to 25% of the total number of shares subject to the option on the 12-month anniversary of the vesting commencement date of June 8, 2020, and the remainder of the option vested and became exercisable over 48 equal installments on each monthly anniversary thereafter.

Open market sale pursuant to a previously established Rule 10b5-1 trading plan adopted by the reporting person on February 10, 2026. The trading schedule, including sale periods and the number of shares to be sold, was established at the time of the trading plan's adoption in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

Open market sale pursuant to a previously established Rule 10b5-1 trading plan adopted by the reporting person on February 10, 2026. The trading schedule, including sale periods and the number of shares to be sold, was established at the time of the trading plan's adoption in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

This option vests and becomes exercisable over 48 equal monthly installments, with a vesting commencement date of April 1, 2023. Installments vest and become exercisable on each monthly anniversary thereafter.

This option vested and became exercisable over 48 equal monthly installments, with a vesting commencement date of April 1, 2022. Installments vested and became exercisable on each monthly anniversary thereafter.

This option shall vest and become exercisable over 48 equal monthly installments, with a vesting commencement date of April 1, 2023. Installments vest and become exercisable on each monthly anniversary thereafter.

This transaction was executed in multiple trades at prices ranging from $18.32 to $18.90. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions referenced in this footnote were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

This option shall vest and become exercisable over 48 equal monthly installments, with a vesting commencement date of April 1, 2023. Installments vest and become exercisable on each monthly anniversary thereafter.

This transaction was executed in multiple trades at prices ranging from $18.55 to $18.77. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions referenced in this footnote were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

This transaction was executed in multiple trades at prices ranging from $19.00 to $19.10. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions referenced in this footnote were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

This transaction was executed in multiple trades at prices ranging from $18.85 to $18.92. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions referenced in this footnote were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

This transaction was executed in multiple trades at prices ranging from $18.50 to $18.56. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions referenced in this footnote were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

This option vests and becomes exercisable over 48 equal monthly installments, with a vesting commencement date of April 1, 2023. Installments vest and become exercisable on each monthly anniversary thereafter.

Open market sale pursuant to a previously established Rule 10b5-1 trading plan adopted by the reporting person on February 10, 2026. The trading schedule, including sale periods and the number of shares to be sold, was established at the time of the trading plan's adoption in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

This option vests and becomes exercisable over 48 equal monthly installments, with a vesting commencement date of April 1, 2023. Installments vest and become exercisable on each monthly anniversary thereafter.

This option vests and becomes exercisable over 48 equal monthly installments, with a vesting commencement date of April 1, 2022. Installments vest and become exercisable on each monthly anniversary thereafter.

Open market sale pursuant to a previously established Rule 10b5-1 trading plan adopted by the reporting person on February 10, 2026. The trading schedule, including sale periods and the number of shares to be sold, was established at the time of the trading plan's adoption in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

This transaction was executed in multiple trades at prices ranging from $18.23 to $18.72. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions referenced in this footnote were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

Open market sale pursuant to a previously established Rule 10b5-1 trading plan adopted by the reporting person on February 10, 2026. The trading schedule, including sale periods and the number of shares to be sold, was established at the time of the trading plan's adoption in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

This option vests and becomes exercisable over 48 equal monthly installments, with a vesting commencement date of April 1, 2022. Installments vest and become exercisable on each monthly anniversary thereafter.

This option shall vest and become exercisable in equal annual installments over a three-year period beginning on the first anniversary of the date of grant.

One-third of the total number of shares subject to the option will vest and become exercisable on August 1, 2027. The remaining shares shall vest in 32 equal monthly installments on the first day of each month thereafter.

One-third of the total number of shares subject to the option will vest and become exercisable on August 1, 2027. The remaining shares shall vest in 32 equal monthly installments on the first day of each month thereafter.

One-third of the total number of shares subject to the option will vest and become exercisable on August 1, 2027. The remaining shares shall vest in 32 equal monthly installments on the first day of each month thereafter.

Pursuant to Omeros Corporation's non-employee director compensation policy, on the date of each annual meeting of shareholders, each non-employee director who has served as a director for at least six months and who will continue to serve as a director after the annual meeting is automatically granted an option to purchase 15,000 shares of common stock. This Form 4 reports the annual stock option award granted to the reporting person in conjunction with the annual meeting of shareholders held on June 18, 2026.

This option will fully vest and become exercisable on the day before the date of the 2027 annual meeting of the shareholders of Omeros Corporation, provided that the reporting person continues to serve as a director of the company through such date.

Pursuant to Omeros Corporation's non-employee director compensation policy, on the date of each annual meeting of shareholders, each non-employee director who has served as a director for at least six months and who will continue to serve as a director after the annual meeting is automatically granted an option to purchase 15,000 shares of common stock. This Form 4 reports the annual stock option award granted to the reporting person in conjunction with the annual meeting of shareholders held on June 18, 2026.

This option will fully vest and become exercisable on the day before the date of the 2027 annual meeting of the shareholders of Omeros Corporation, provided that the reporting person continues to serve as a director of the company through such date.

Pursuant to Omeros Corporation's non-employee director compensation policy, on the date of each annual meeting of shareholders, each non-employee director who has served as a director for at least six months and who will continue to serve as a director after the annual meeting is automatically granted an option to purchase 15,000 shares of common stock. This Form 4 reports the annual stock option award granted to the reporting person in conjunction with the annual meeting of shareholders held on June 18, 2026.

This option will fully vest and become exercisable on the day before the date of the 2027 annual meeting of the shareholders of Omeros Corporation, provided that the reporting person continues to serve as a director of the company through such date.

Pursuant to Omeros Corporation's non-employee director compensation policy, on the date of each annual meeting of shareholders, each non-employee director who has served as a director for at least six months and who will continue to serve as a director after the annual meeting is automatically granted an option to purchase 15,000 shares of common stock. This Form 4 reports the annual stock option award granted to the reporting person in conjunction with the annual meeting of shareholders held on June 18, 2026.

This option will fully vest and become exercisable on the day before the date of the 2027 annual meeting of the shareholders of Omeros Corporation, provided that the reporting person continues to serve as a director of the company through such date.

Pursuant to Omeros Corporation's non-employee director compensation policy, on the date of each annual meeting of shareholders, each non-employee director who has served as a director for at least six months and who will continue to serve as a director after the annual meeting is automatically granted an option to purchase 15,000 shares of common stock. This Form 4 reports the annual stock option award granted to the reporting person in conjunction with the annual meeting of shareholders held on June 18, 2026.

This option will fully vest and become exercisable on the day before the date of the 2027 annual meeting of the shareholders of Omeros Corporation, provided that the reporting person continues to serve as a director of the company through such date.

Pursuant to Omeros Corporation's non-employee director compensation policy, on the date of each annual meeting of shareholders, each non-employee director who has served as a director for at least six months and who will continue to serve as a director after the annual meeting is automatically granted an option to purchase 15,000 shares of common stock. This Form 4 reports the annual stock option award granted to the reporting person in conjunction with the annual meeting of shareholders held on June 18, 2026.

This option will fully vest and become exercisable on the day before the date of the 2027 annual meeting of the shareholders of Omeros Corporation, provided that the reporting person continues to serve as a director of the company through such date.